10.25384/SAGE.11417742.v1
Vincenzo Adamo
Vincenzo
Adamo
Giuseppina Rosaria Rita Ricciardi
Giuseppina Rosaria Rita
Ricciardi
Dario Giuffrida
Dario
Giuffrida
Giuseppa Scandurra
Giuseppa
Scandurra
Antonio Russo
Antonio
Russo
Livio Blasi
Livio
Blasi
Pietro Spadaro
Pietro
Spadaro
Carmelo Iacono
Carmelo
Iacono
Hector J. Soto Parra
Hector J.
Soto Parra
Antonino Savarino
Antonino
Savarino
Francesco Ferraú
Francesco
Ferraú
Filippo Zerilli
Filippo
Zerilli
Francesco Verderame
Francesco
Verderame
Alfredo Butera
Alfredo
Butera
Carlo Santangelo
Carlo
Santangelo
Veronica Franchina
Veronica
Franchina
Michele Caruso
Michele
Caruso
TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
SAGE Journals
2019
eribulin
metastatic breast cancer
multicentre
prospective
real world
third line
2019-12-20 13:07:16
Journal contribution
https://sage.figshare.com/articles/journal_contribution/TAM895755_Supplementary_material_CLN_Supplemental_material_for_Eribulin_mesylate_use_as_third-line_therapy_in_patients_with_metastatic_breast_cancer_VESPRY_a_prospective_multicentre_observational_study/11417742
<p>Supplemental material, TAM895755_Supplementary_material_CLN for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina and Michele Caruso in Therapeutic Advances in Medical Oncology</p>